Dr. Jared Weiss details the importance of continued research into novel therapies for patients with lung cancer.

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

Shares of Amgen (AMGN) were in the spotlight on Monday morning after the company announced that its immunotherapy Imdelltra ...

SMMT's HARMONi trial shows PFS benefits for ivonescimab in EGFR-mutant NSCLC, but lack of proven overall survival raises ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

Tracking the trajectory of symptoms may be an improvement over the traditional way of collecting patient-reported outcomes ...

Jazz Pharmaceuticals' study shows Zepzelca with atezolizumab boosts survival in small cell lung cancer, cutting progression ...

Summit Therapeutics said its closely tracked antibody, the first lung cancer drug to beat Merck’s Keytruda in a head-to-head ...

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...